Fortunato Ciardiello

Molecular Biology · 2000–2019

A researcher in the Science corpus: 16 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 87 citations into it

Whom Fortunato Ciardiello trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. N. Ferrara
2. R. Kerbel
3. Rakesh K. Jain
4. J. Baselga
5. J. Folkman
6. N. Hynes
7. Tony Pawson

Who trusts Fortunato Ciardiello overall

1. J. Mendelsohn
2. J. Baselga
3. Ping Wee
4. G. Tortora
5. T. Mitsudomi
6. H. Schwarzenbach

Papers from Fortunato Ciardiello's perspective

Ordered by how strongly the researchers Fortunato Ciardiello trusts endorse each paper. Same corpus, a different order for every researcher.

1. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (Annals of Oncology)
2. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. (Journal of Clinical Oncology)
3. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (Cancer Research)
4. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (Journal of Clinical Oncology)
5. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. (Journal of Clinical Oncology)
6. Tumor angiogenesis (Advances in Cancer Research)
7. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (Journal of Clinical Oncology)
8. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
9. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (Journal of Clinical Oncology)
10. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (Journal of Clinical Oncology)

Their papers

• Chronic inflammation and oxidative stress in human carcinogenesis (2007) — 987 citations
• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (2019) — 1,107 citations
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) — 774 citations
• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017) — 665 citations
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2016) — 4,239 citations
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) — 3,178 citations
• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) — 867 citations
• Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) — 760 citations
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) — 1,471 citations
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (2011) — 1,899 citations
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) — 2,124 citations
• EGFR antagonists in cancer treatment. (2008) — 2,077 citations
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) — 632 citations
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001) — 1,039 citations
• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. (2001) — 662 citations
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (2000) — 998 citations